Clinical Research Directory
Browse clinical research sites, groups, and studies.
Anifrolumab Malignancy and Serious Infections Study
Sponsor: AstraZeneca
Summary
This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.
Official title: A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab
Key Details
Gender
All
Age Range
18 Years - 130 Years
Study Type
OBSERVATIONAL
Enrollment
3195
Start Date
2026-01-26
Completion Date
2031-11-30
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
Anifrolumab
Anifrolumab prescribed per local practice
Locations (4)
Research Site
Copenhagen, Denmark
Research Site
Charenton-le-Pont, France
Research Site
Essen, Germany
Research Site
Barcelona, Spain